![Wladimir Hogenhuis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wladimir Hogenhuis
Director/Board Member at
REZOLUTE, INC.
Net worth: 622 310 $ as of 2026-06-29
Profile
Wladimir Hogenhuis currently works at Driver Bioengineering, Inc., as President, Chief Executive Officer & Director from 2022, Rezolute, Inc., as Independent Director from 2021, GATT Technologies BV, as Director from 2020, and IHP Therapeutics, Inc., as Director.
Mr. Hogenhuis also formerly worked at Vision 2020, as Director, Merck & Co., Inc., as General Manager-Neuroscience, Ultragenyx Pharmaceutical, Inc., as Chief Operating Officer from 2018 to 2020, and GSK Plc, as Senior Vice President from 2012 to 2018.
Mr. Hogenhuis received his doctorate degree from the University of Leiden and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REZOLUTE, INC. 0.14% | 2025-12-15 | 119,675 ( 0.14% ) | 622 310 $ | 2026-06-29 |
Wladimir Hogenhuis active positions
| Companies | Position | Start |
|---|---|---|
| REZOLUTE, INC. | Director/Board Member | 2021-03-01 |
GATT Technologies BV
 GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Director/Board Member | 2020-04-30 |
IHP Therapeutics, Inc. | Director/Board Member | - |
Driver Bioengineering, Inc.
 Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Chief Executive Officer | 2022-04-27 |
Former positions of Wladimir Hogenhuis
| Companies | Position | End |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Chief Operating Officer | 2020-01-09 |
| GSK PLC | Corporate Officer/Principal | 2018-08-31 |
Vision 2020 | Director/Board Member | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Training of Wladimir Hogenhuis
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
68
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vision 2020 | |
Rezolute, Inc.
 Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Health Technology |
IHP Therapeutics, Inc. |
- Stock Market
- Insiders
- Wladimir Hogenhuis
